Introduction
============

In developed countries, 40% of breast cancer patients are older than 65 years of age at diagnosis and this percentage is increasing \[[@B1]\]. Old age is predictive for comorbidity and decreased functioning \[[@B2],[@B3]\]. Therefore, these factors might influence treatment decisions in elderly breast cancer patients. Previous studies have shown that elderly breast cancer patients receive less aggressive treatment \[[@B4]\] and have a higher disease-specific mortality, even with 65% of breast cancer patients above 75 years dying from other causes than breast cancer \[[@B5]\].

The most recent guidelines of the International Society of Geriatric Oncology and the European Society of Breast Cancer Specialists (EUSOMA) advise breast conserving surgery with whole-breast radiotherapy or mastectomy followed by postoperative radiotherapy in selected patients as standard care for elderly breast cancer patients \[[@B6]\]. However, the National Comprehensive Cancer Network guidelines state that omission of radiotherapy may be considered in patients of 70 years or older with stage I estrogen receptor-positive breast cancer who undergo a lumpectomy with negative margins and are receiving endocrine therapy \[[@B7]\]. This shows that there is still no consensus on how to treat elderly breast cancer patients. Also, elderly patients are often not treated according to guidelines \[[@B8],[@B9]\]. Comorbid conditions and frailty are, besides age and patient and physician\'s preference, important reasons to deviate from the guidelines \[[@B10],[@B11]\]. Besides, treatment strategies for elderly breast cancer patients are mostly not evidence-based because elderly are often not included in clinical trials due to age restrictions or comorbidity \[[@B12]\].

Breast surgery is generally considered as low-morbidity surgery \[[@B13]\]. However, a variety of complications can occur with serious consequences. For example, surgical site infections can lead to increased morbidity, additional costs and delay of postoperative adjuvant therapies \[[@B13]\].

In order to develop evidence-based guidelines for tailored care of breast cancer in the elderly, it is important to investigate the occurrence of complications of surgery in this specific group. Only few studies concerning postoperative complications in elderly breast cancer patients have been performed, often with a limited number of patients \[[@B11],[@B14],[@B15]\]. Therefore, the objective of this study was to identify risk factors for postoperative complications in elderly breast cancer patients, and to evaluate overall survival in patients with postoperative complications compared with patients without postoperative complications.

Methods
=======

We considered all consecutive female patients aged 65 years and older with invasive and in situ breast cancer who were diagnosed and treated between 1997 and 2012 in the Department of General and Geriatric Surgery of the University of Naples \"Federico II\".

We reviewed the charts of these patients and collected information on specific treatments, comorbidities, adverse events, geriatric parameters, body mass index (BMI), smoking and mortality.

For this study, all patients with breast cancer stage I-IV and in situ of all histological subtypes who were treated with breast conserving surgery or mastectomy were included. If patients received breast-conserving surgery (BCS) followed by mastectomy, the most extensive surgery was used for analyses. Stage was described using the pathological tumor-node-metastasis (TNM) classification, as valid in the year of diagnosis. If the pathological stage was missing, clinical stage was used. Axillary surgery was defined as a sentinel node procedure or an axillary lymph node dissection. Again, the most extensive axillary surgery was used for the analyses.

To compare different age groups, patients were categorized into five groups: 65-69, 70-74, 75-79, 80-84, and 85 years or older.

Number of concomitant diseases was categorized in four groups: no concomitant disease, 1 concomitant disease, 2 concomitant diseases and 3 or more concomitant diseases \[[@B16]\]. BMI was analyzed in three groups: \<20, 20-25, and \>25.

In case of missing data, patients were not excluded from the analyses, but analyzed in a separate group (unknown).

The possible postoperative complications were wound infections (including abscesses), bleeding, hematoma, seroma, anemia, cardiovascular complications, thrombo-embolisms and other complications. The primary outcome was defined as having one or more of these complications.

Statistical analyses
====================

All statistical analyses were two-sided. A p value smaller than 0.05 was considered as significant.

The following risk factors for having at least one post-operative complication were assessed in univariable logistic regression models: age (in groups per 5 years), stage according to the TNM-classification, most extensive surgery, most extensive axillary surgery, number of comorbid conditions, polypharmacy (5 or more types of drugs per day), neoadjuvant treatment, BMI, and smoking at time of surgery.

Results
=======

Patient characteristics
-----------------------

Overall, 449 patients of 65 years and older with invasive and in situ breast cancer underwent BCS or mastectomy and were included for analyses. Patient characteristics are shown in Table [1](#T1){ref-type="table"}.

###### 

Patients characteristics.

  PATIENTS\' CHARACTERISTICS       n (449)        \%
  -------------------------------- -------------- -------
  MEDIAN AGE (range)               76.0 (65-92)   
                                                  
  AGE                                             
                                                  
  65-69                            131            29,5%
                                                  
  70-74                            114            25,1%
                                                  
  75-79                            87             19,3%
                                                  
  80-84                            68             15,2%
                                                  
  \>85                             49             10,9%
                                                  
  N OF CONCOMITANT DISEASE                        
                                                  
  0                                113            25,2%
                                                  
  1                                112            25,0%
                                                  
  2                                106            23,6%
                                                  
  \> = 3                           118            26,2%
                                                  
  TNM STAGE                                       
                                                  
  IN SITU                          17             3,9%
                                                  
  I                                168            37,5%
                                                  
  II                               180            40,1%
                                                  
  III                              39             8,8%
                                                  
  IV                               4              1,0%
                                                  
  UNKNOWN                          41             8,7%
                                                  
  NEOADJUVANT TREATMENT                           
                                                  
  NO NEOADJUVANT TREATMENT         436            97%
                                                  
  NEOADJUVANT CHEMOTHERAPY         13             3%
                                                  
  BREAST SURGERY                                  
                                                  
  BREAST CONSERVING SURGERY        125            28%
                                                  
  MASTECTOMY                       324            72%
                                                  
  AXILLARY SURGERY                                
                                                  
  NO AXILLARY SURGERY              40             9%
                                                  
  SENTINEL NODE BIOPSY             180            40%
                                                  
  AXILLARY LYMPH NODE DISSECTION   229            51%
                                                  
  BMI                                             
                                                  
  \<20                             4              1%
                                                  
  20-25                            86             19,1%
                                                  
  \>25                             135            30,1%
                                                  
  UNKNOWN                          224            49,8%
                                                  
  POLYPHARMACY                                    
                                                  
  NO                               354            79%
                                                  
  YES                              95             21%
                                                  
  SMOKING AT TIME OF DIAGNOSIS                    
                                                  
  NO                               276            61,5%
                                                  
  YES                              31             6,9%
                                                  
  UNKNOWN                          142            31,6%

Most patients (72%) were treated with mastectomy. The majority of patients (74.8%) had at least one concomitant disease. Few patients (3.0%) received neoadjuvant treatment. 21% of the patients used 5 or more types of drugs per day. BMI values were missing in 224 patients (49.8%) and data about smoking were missing in 142 patients (31.6%). Median follow up was 7.5 years (range 0.01 -15.0).

Postoperative complications
---------------------------

Overall, 18.2% of patients developed 1 or more postoperative complications (Table [2](#T2){ref-type="table"}). The most frequent complications were seroma (n = 21) and wound infection (n = 17).

###### 

Complications in different age groups.

                                TOTAL        65-69       70-74        75-79        80-84        \> = 85
  ----------------------------- ------------ ----------- ------------ ------------ ------------ ------------
  ALL COMPLICATIONS             82 (18,2%)   13 (9,9%)   15 (13,2%)   17 (19,5%)   18 (26,5%)   19 (38,8%)
                                                                                                
  WOUND INFECTION               17 (3,8%)    3           4            4            3            3
                                                                                                
  BLEEDING                      14 (3,2%)    4           2            2            3            3
                                                                                                
  HEMATOMA                      14 (3,2%)    3           2            4            3            2
                                                                                                
  SEROMA                        21 (4,8%)    2           4            5            4            6
                                                                                                
  ANEMIA                        2 (0,4%)     0           0            0            1            1
                                                                                                
  CARDIOVASCULAR COMPLICATION   8 (1,4%)     0           2            2            2            2
                                                                                                
  THROMBO-EMBOLISM              4 (1,0%)     1           1            0            1            1
                                                                                                
  OTHER COMPLICATIONS           2 (0,4%)     0           0            0            1            1

As shown in Table [3](#T3){ref-type="table"}, the odds ratio (OR) for developing a postoperative complication increased with age (OR for patients aged \> 85 years was 5.75 (95% confidence interval 2.38-14.04, p \< 0.001) in a univariable logistic regression model).

###### 

Association between patient, tumor characteristics, treatment and occurrence of postoperative complications.

                                   N OF PATIENTS WITH COMPLICATION (%)   OR      95% CI       p value
  -------------------------------- ------------------------------------- ------- ------------ ----------
  AGE                                                                                         
                                                                                              
  65-69                            13 (9,9%)                             Ref                  
                                                                                              
  70-74                            15 (13,2%)                            1,37    0,58-3,24    ns
                                                                                              
  75-79                            17 (19,5%)                            2,20    0,95-5,16    ns
                                                                                              
  80-84                            18 (26,5%)                            3,27    1,40-7,72    0,004
                                                                                              
  \> = 85                          19 (38,8%)                            5,75    2,38-14,04   \<0,001
                                                                                              
  N OF CONCOMITANT DISEASE                                                                    
                                                                                              
  0                                13 (12,0%)                            Ref                  
                                                                                              
  1                                20 (18,3%)                            1,67    0,74-3,80    ns
                                                                                              
  2                                20 (18,5%)                            1,79    0,80-4,07    ns
                                                                                              
  \> = 3                           29 (24,6%)                            2,51    1,17-5,45    0,01
                                                                                              
  POLYPHARMACY                                                                                
                                                                                              
  NO                               27 (7,6%)                             Ref                  
                                                                                              
  YES                              55 (57,9%)                            16,65   9,12-30,58   \<0.0001
                                                                                              
  BREAST SURGERY                                                                              
                                                                                              
  BREAST CONSERVING SURGERY        29 (23,2%)                            Ref                  
                                                                                              
  MASTECTOMY                       53 (16,4%)                            0.65    0,38-1,11    ns
                                                                                              
  AXILLARY SURGERY                                                                            
                                                                                              
  NO AXILLARY SURGERY              5 (12,5%)                             Ref                  
                                                                                              
  SENTINEL NODE BIOPSY             31 (17,2%)                            1,46    0,49-4.60    ns
                                                                                              
  AXILLARY LYMPH NODE DISSECTION   46 (20,1%)                            1,76    0,61-5,43    ns
                                                                                              
  NEOADJUVANT CHEMOTHERAPY                                                                    
                                                                                              
  NO NEOADJUVANT TREATMENT         76 (17,4%)                            Ref                  
                                                                                              
  NEOADJUVANT CHEMOTHERAPY         6 (46,1%)                             4,06    1,17-13,92   \<0,05
                                                                                              
  TNM STAGE                                                                                   
                                                                                              
  IN SITU                          4 (23,5%)                                                  
                                                                                              
  I                                27 (16,1%)                            Ref                  
                                                                                              
  II                               25 (13,9%)                            0,84    0,45-1,58    ns
                                                                                              
  III                              8 (20,5%)                             1,35    0,51-3,49    ns
                                                                                              
  IV                               1 (25%)                               1,74    0,07-19,99   ns
                                                                                              
  UNKNOWN                          17 (41,5%)                                                 
                                                                                              
  BMI                                                                                         
                                                                                              
  \<20                             1 (25%)                               2,06    0,08-25,85   ns
                                                                                              
  20-25                            12 (14%)                              Ref                  
                                                                                              
  \>25                             31 (23%)                              1,84    0,84-4,08    ns
                                                                                              
  UNKNOWN                          38 (17%)                                                   
                                                                                              
  SMOKING AT TIME OF DIAGNOSIS                                                                
                                                                                              
  NO                               46 (16,7%)                            Ref                  
                                                                                              
  YES                              11 (35,5%)                            2,75    1,14-6,54    \<0,05
                                                                                              
  UNKNOWN                          25 (17,6%)                                                 

A higher number of concomitant diseases was associated with a higher risk of postoperative complications (patients without concomitant disease functioned as a reference; OR was 1.67 (95% CI 0.74-3.80), 1.79 (95% CI 0.80-4.07) and 2.51 (95% CI 1.17-5.45; p = 0.01) in patients with 1, 2 and 3 or more concomitant diseases, respectively).

Similarly, polypharmacy was strongly associated with risk of complications (OR 16.7 (95% CI 9.12-30.58), p \< 0.0001).

Furthermore, patients who received a mastectomy and patients who underwent axillary lymph node dissection had more complications than patients who were treated with breast conserving surgery and less extensive axillary surgery.

Smoking increased the odds for developing a complication with an OR of 2.75 (95% CI 1.14-6.54, p \< 0.05).

There was no significant association between BMI and postoperative complications.

Overall survival was worse in patients with postoperative complications \[HR 2,06 (95% CI 1,52-2,70), p \< 0,001\] (Table [4](#T4){ref-type="table"}). This increased risk of mortality is probably due to geriatric parameters such as comorbidity or poor physical function, more than to higher complication rates.

###### 

Survival analyses for one or more postoperative complications versus no postoperative complications.

                                   DEATHS   5-YEAR SURVIVAL (%)   HR     95% CI      p value
  -------------------------------- -------- --------------------- ------ ----------- ----------
  OVERALL SURVIVAL                 133      70                                       
                                                                                     
  No postoperative complications   91       75                    Ref                
                                                                                     
  Postoperative complications      42       49                    2,06   1,52-2,70   \< 0,001

Discussion
==========

This study shows that the number of concomitant diseases and polypharmacy are strongly related to the occurrence of postoperative complications in elderly breast cancer patients.

Patients treated with mastectomy had more complications than patients who received breast conserving surgery.

Elderly patients had complications more often, but after adjustment for tumor stage, comorbidity, and treatment, only a trend for increasing risk of complications in higher age groups was observed.

Overall survival was worse in patients with one or more postoperative complications.

The increased risk for early and late overall mortality is probably not due to the complications in itself, but can be explained by the frail state of the patients who develop postoperative complications, since comorbidity in itself increases the risk of mortality in elderly breast cancer patients \[[@B17],[@B18]\].

Concerning the impact of comorbidity on developing postoperative complications, Houterman et al. \[[@B15]\] concluded from an observational study that comorbidity and age did not influence the occurrence of complications after treatment. The study included only 154 patients aged 70 years or older, and investigated complications of all types of therapy in the first year after diagnosis. Also, patients who did not receive surgery were included in this study. Therefore, this study differs considerably from the current study, which might explain the differences in outcome. Another study by Janssen-Heijnen et al. \[[@B14]\] also found no association between comorbidity and postoperative complications. Again, this study included only 490 patients with breast cancer, of whom only 192 were older than 65. Since the impact of comorbid disease is the highest in the eldest elderly, this might explain the differences with the current study.

A recent Danish study \[[@B19]\] found that older age and mastectomy increases the risk of re-operation due to bleeding in breast cancer surgery. These results were confirmed in the current study.

Another study \[[@B20]\] found that BMI \> 25, diabetes, and smoking were predictors of wound complications. In the current study, BMI was not related to risk of postoperative complications, which might be explained by missing values in about 50% of patients, since BMI registration in a chart may not be missing at random.

Since elderly patients are rarely included in clinical trials \[[@B12]\], large cohort studies are of great importance in this population. These studies are a good way of studying complications of treatment, since data are unbiased and the studies generally contain more patients \[[@B21]\].

This study also has some limitations. Due to the retrospectively collection of data, there might have been an underestimation of the number of complications. However, in these data, 18.2% of patients developed at least one complication, and this is even higher than a recent study in a large cohort in the U.S. \[[@B20]\] which reported a 30-day morbidity rate for all breast cancer procedures of 5.6%. The most common complications were wound infections. Therefore, these data seem to accurately reflect general practice and correspond with previous studies.

A meta-analysis has confirmed that hormonal treatment as monotherapy is inferior to surgery (with or without hormonal treatment) for the local control and progression-free survival of breast cancer in medically fit older women \[[@B22]-[@B25]\].

However, in Italy, elderly patients receive less surgery and more hormonal therapy as monotherapy than younger patients, even in lower stages of disease \[[@B4]\].

This suggests that patients might be undertreated due to fear of morbidity and mortality in breast cancer surgery. Although elderly patients with comorbidity do have a higher risk of postoperative complications, relative mortality was not higher in this group and therefore suggests that omitting surgery because of fear for treatment-related mortality is only justified in vulnerable elderly patients. The question remains how to identify this specific group. Therefore, future prospective studies are needed to identify patients at risk for postoperative complications, and to develop tailored care for elderly breast cancer patients.
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